| Literature DB >> 15706481 |
Ron Hoffman1, Benjamin Brenner.
Abstract
Women experience increased thrombotic risk at pregnancy and puerperium as well as during hormonal therapy with oral contraceptives or hormone replacement therapy. Physiological and anatomical changes in pregnancy contribute to the hypercoagulable situation. Women with thrombophilia have an increased risk for venous and arterial thromboembolism as well as for gestational vascular complications including fetal loss, pre-eclampsia, placental abruption, and fetal growth restriction. Children are at increased thrombotic risk, particularly at the neonatal period, and may express thrombosis often in association with thrombophilia. This article will focuses on the clinical association, pathogenesis, and treatment of thrombophilia-related issues in women and children.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15706481 DOI: 10.1055/s-2005-863811
Source DB: PubMed Journal: Semin Thromb Hemost ISSN: 0094-6176 Impact factor: 4.180